Standard BioTools Inc.
LAB
$1.07
-$0.045-4.04%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 23.59% | -26.48% | 41.08% | -42.17% | -62.61% |
| Total Depreciation and Amortization | 5.51% | -37.93% | 44.72% | -15.27% | 32.97% |
| Total Amortization of Deferred Charges | -- | -- | -360.73% | -- | -- |
| Total Other Non-Cash Items | -10.83% | 36.36% | -13.70% | 152.53% | -397.49% |
| Change in Net Operating Assets | -294.57% | 174.98% | -165.57% | 82.11% | -776.77% |
| Cash from Operations | -115.40% | 49.55% | 28.63% | 37.50% | -344.32% |
| Capital Expenditure | -49.44% | -49.98% | -16.42% | -148.02% | -901.28% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -100.00% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -35.46% | 206.51% | -154.85% | 34.44% | 397.75% |
| Cash from Investing | -43.15% | 183.30% | -161.45% | -84.20% | 2,524.91% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 100.00% | -555.36% |
| Issuance of Common Stock | -- | 672.06% | -95.16% | 1,851.39% | -82.90% |
| Repurchase of Common Stock | -2.22% | 35.71% | 99.76% | -168.94% | -6,260.92% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | -- |
| Cash from Financing | 99.92% | -2,725,900.00% | 99.99% | -43.72% | -1,867.40% |
| Foreign Exchange rate Adjustments | 233.71% | 34.56% | -358.43% | -323.81% | -109.13% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 64.41% | 27.12% | -243.09% | -107.31% | 943.78% |